BCLI Brainstorm Cell Therapeutics Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

BCLI [NASD]

Brainstorm Cell Therapeutics Inc.

Healthcare | Biotechnology | USA

financial highlights | statements

Index	-	P/E	-	EPS (ttm)	-0.69	Insider Own	1.40%	Shs Outstand	21.67M	Perf Week	-5.01%
Market Cap	82.13M	Forward P/E	-	EPS next Y	-0.15	Insider Trans	0.49%	Shs Float	18.94M	Perf Month	-5.49%
Income	-13.90M	PEG	-	EPS next Q	-0.04	Inst Own	11.80%	Short Float	5.73%	Perf Quarter	9.22%
Sales	-	P/S	-	EPS this Y	-164.50%	Inst Trans	-	Short Ratio	15.64	Perf Half Y	7.67%
Book/sh	0.24	P/B	15.79	EPS next Y	64.10%	ROA	-100.70%	Target Price	10.50	Perf Year	11.80%
Cash/sh	0.32	P/C	11.73	EPS next 5Y	-	ROE	-176.00%	52W Range	2.92 - 5.35	Perf YTD	6.76%
Dividend	-	P/FCF	-	EPS past 5Y	-8.90%	ROI	-	52W High	-29.16%	Beta	1.33
Dividend %	-	Quick Ratio	1.70	Sales past 5Y	-	Gross Margin	-	52W Low	29.79%	ATR	0.12
Employees	31	Current Ratio	1.70	Sales Q/Q	-	Oper. Margin	-	RSI (14)	28.98	Volatility	4.27% 3.00%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.70	Prev Close	3.82
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 13 BMO	Payout	-	Avg Volume	69.40K	Price	3.79
Recom	2.00	SMA20	-8.36%	SMA50	-5.50%	SMA200	1.72%	Volume	48,581	Change	-0.79%

Dec-19-16

Reiterated

Maxim Group

Buy

$5 → $6

Dec-22-15

Reiterated

Maxim Group

Buy

$14 → $5

Apr-04-19 10:30AM	BCLI: Two Abstracts to be Presented at AAN Annual Meeting Zacks Small Cap Research
Mar-28-19 04:30AM	Two BrainStorm Scientific Abstracts Accepted for Presentation at the 71st American Academy of Neurology Annual Meeting GlobeNewswire
Mar-26-19 06:30AM	BrainStorm Announces Grant of an additional New European Patent for NurOwn® GlobeNewswire
Mar-18-19 10:26PM	Atlas Blockchain Announces Definitive Agreement for the Acquisition of Isracann and Amendment to Investor Services Agreement GlobeNewswire
Mar-15-19 10:50AM	BCLI: Hospital Exemption Approved in Israel; First Patient Enrolled in Phase 2 Study in Progressive MS Zacks Small Cap Research
Mar-14-19 01:00AM	BrainStorm Announces First Patient Enrolled in Phase 2 Clinical Trial of Progressive MS GlobeNewswire
Mar-13-19 11:57AM	Breakeven On The Horizon For Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Simply Wall St.
Mar-12-19 07:47AM	The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug Benzinga
Mar-07-19 04:00AM	BrainStorm to Host Business Update Conference Call GlobeNewswire
Feb-22-19 07:30AM	BrainStorm Announces First Contracted U.S. Clinical Site for Phase 2 Progressive MS Study GlobeNewswire
Feb-21-19 06:00AM	BrainStorm to Present at 2019 Sachs Associates European Life Sciences CEO Forum in Zurich, Switzerland GlobeNewswire
Feb-19-19 08:06AM	BrainStorm Issues a Statement to Patients and Shareholders GlobeNewswire
Feb-04-19 08:22AM	BrainStorm to Present at 2019 BIO CEO & Investor Conference and Extracellular Vesicles in Diagnostics & Therapeutics Symposium GlobeNewswire
Jan-25-19 07:15AM	BrainStorm Cell Therapeutics to Present at the 2019 NobleCon15 Annual Investor Conference in Fort Lauderdale, Florida GlobeNewswire
Jan-22-19 08:40AM	BrainStorm Granted Additional Patent for NurOwn® in Israel GlobeNewswire
Jan-11-19 12:05AM	BrainStorm to Present NurOwn® Phase 3 Study Update at the 9th Annual California ALS Research Summit in Irvine, CA GlobeNewswire
Jan-07-19 01:30PM	BCLI: Initiating Phase 2 Study in Progressive Multiple Sclerosis Zacks Small Cap Research
Jan-03-19 06:04AM	BrainStorm Cell Therapeutics to Present at the 2019 Biotech Showcase and Sachs Associates Neuroscience Innovation Forum at JPM Week GlobeNewswire
Dec-27-18 07:35AM	BrainStorm Issues 2018 Letter to Shareholders GlobeNewswire
Dec-26-18 01:00AM	BrainStorm Expands Manufacturing of NurOwn® for Phase 2 Progressive MS Trial GlobeNewswire
Dec-17-18 07:34AM	FDA Accepts BrainStorms NurOwn® IND Application for Progressive Multiple Sclerosis GlobeNewswire
07:21AM	BrainStorm gets FDA okay for stem cell trial in MS patients Reuters
Dec-04-18 08:00AM	BrainStorm Cell Therapeutics to Present at the 29th International Symposium on ALS/MND GlobeNewswire
Dec-03-18 01:53PM	Do Institutions Own Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) Shares? Simply Wall St.
Nov-21-18 08:30AM	Detailed Research: Economic Perspectives on Stellar Biotechnologies, MAM Software Group, EverQuote, Brainstorm Cell Therapeutics, Mid-Con Energy Partners, LP, and Staffing 360 Solutions What Drives Growth in Today's Competitive Landscape GlobeNewswire
Nov-19-18 08:00AM	BrainStorm Cell Therapeutics Announces Submission of IND for NurOwn® in Progressive Multiple Sclerosis GlobeNewswire
Nov-07-18 08:00AM	BrainStorm Cell Therapeutics to Present at November Clinical and Investor Conferences GlobeNewswire
Oct-30-18 10:15AM	BCLI: Phase 3 Trial to Be Fully Enrolled by Mid-2019 Zacks Small Cap Research
Oct-29-18 08:00AM	BrainStorm Announces Financial Results for the Third Quarter of 2018 and Provides a Corporate Update GlobeNewswire
Oct-17-18 08:30AM	BrainStorm to Announce Third Quarter Financial Results and Provide Corporate Update on Monday, October 29 GlobeNewswire
Oct-04-18 11:23AM	Does Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) Fall With The Market? Simply Wall St.
Oct-03-18 06:10AM	BrainStorm Highlights Translational Data and Presentations Supporting NUROWN® Technology Platform as a Best-In-Class Strategy in ALS GlobeNewswire
Sep-13-18 07:30AM	BrainStorm Granted New U.S. Patent for Industrial Scale Manufacturing of NurOwn® GlobeNewswire
Sep-12-18 08:49AM	BrainStorm to Present at FDA and Scientific Workshops Highlighting Innovation in ALS Trial Designs and Continued Progress with NurOwn® Cellular Therapy Platform GlobeNewswire
Sep-05-18 11:36AM	BrainStorm Cell Therapeutics Announces New Presentation Time at the H.C. Wainwright & Co. 20th Annual Investor Conference GlobeNewswire
Sep-04-18 08:00AM	BrainStorm Appoints Arturo Araya as Chief Commercial Officer GlobeNewswire
Aug-29-18 08:00AM	BrainStorm Cell Therapeutics to Provide Corporate Update at the H.C. Wainwright & Co 20th Annual Investor Conference GlobeNewswire
Aug-23-18 10:45AM	BCLI: Positive Interim Safety Analysis for Phase 3 Trial Zacks Small Cap Research
08:20AM	BrainStorm Cell Therapeutics Announces Successful Interim Safety Analysis in Phase 3 Trial of NurOwn® Therapy for ALS GlobeNewswire
Jul-25-18 09:03AM	BrainStorm Announces Grant of a New European Patent for NurOwn® PR Newswire
Jul-24-18 10:05AM	BCLI: Phase 3 Trial in ALS Fully Funded; Company to Announced Additional Indications for NurOwn Zacks Small Cap Research
Jul-23-18 08:00AM	BrainStorm Announces Financial Results for the Second Quarter of 2018 and Provides a Corporate Update PR Newswire
06:30AM	Brainstorm Cell Therapeutics Inc. to Host Earnings Call ACCESSWIRE
Jul-17-18 08:32AM	BrainStorm to Announce Second Quarter Financial Results of 2018 and Provide a Corporate Update on Monday July 23 PR Newswire
Jul-05-18 09:40AM	BCLI: Additional Manufacturing Facility Secured for Phase 3 ALS Trial Zacks Small Cap Research +6.31%
07:30AM	BrainStorm Granted Japanese Patent for NurOwn® PR Newswire
07:20AM	Meet the one patient who will get access to this experimental ALS therapy before its approved MarketWatch
Jul-02-18 07:41AM	BrainStorm Announces Second U.S. Manufacturing Site for NurOwn® Production PR Newswire
Jun-28-18 05:00AM	BrainStorm Strengthens Executive Management Team with the Appointment of Susan Ward, Ph.D. and Joseph Petroziello PR Newswire
Jun-26-18 08:05AM	BrainStorm Provides Update on "Right to Try" Policy PR Newswire
Jun-25-18 09:46AM	BrainStorm to Host Tomorrow a Conference Call to Announce Its "Right To Try" Policy PR Newswire
Jun-20-18 01:44PM	The Right to Try Could Cost Dying Patients a Fortune Bloomberg
Jun-13-18 09:06AM	Biotech Executives Fret Over Hassles And Uncertainties Of 'Right To Try' Forbes
Jun-11-18 10:20AM	BCLI: Determining Path Forward Following Right to Try; Warrant Exercise Raises $12.3M Zacks Small Cap Research
Jun-07-18 08:00AM	BrainStorm Announces Exercise of Warrants Resulting in Cash Proceeds of ~$12.3 Million at $5 Share PR Newswire -8.72%
Jun-02-18 06:34PM	Should You Worry About Brainstorm Cell Therapeutics Incs (NASDAQ:BCLI) CEO Pay? Simply Wall St.
Jun-01-18 07:50AM	BrainStorm to Host Call Following President Trump's Citing of Company's ALS Treatment During "Right-to-Try" Bill Signing PR Newswire
May-30-18 01:25AM	BrainStorm Cell Therapeutics to Provide Corporate Update at the BIO International Convention PR Newswire
May-25-18 09:19AM	BrainStorm Cell Therapeutics Issues Statement on "Right to Try" Legislation PR Newswire +6.22%
May-17-18 11:00AM	BCLI: Enrollment in Phase 3 Trial of NurOwn® Continuing on Schedule Zacks Small Cap Research
May-14-18 11:31AM	What Should Investors Know About Brainstorm Cell Therapeutics Incs (NASDAQ:BCLI) Future? Simply Wall St.
08:00AM	BrainStorm Announces First Quarter 2018 Financial Results and Provides Corporate and Clinical Highlights PR Newswire
06:15AM	Brainstorm Cell Therapeutics Inc. to Host Earnings Call ACCESSWIRE
May-09-18 01:00AM	BrainStorm CEO to Present at World Advanced Therapy and Regenerative Medicine Congress in London PR Newswire
May-08-18 08:30AM	Today's Research Reports on Trending Tickers: Cel-Sci Corporation and Brainstorm Cell Therapeutics ACCESSWIRE
07:12AM	Brainstorm to Announce First Quarter Financial Results and Provide Corporate Update on Monday, May 14 PR Newswire
May-01-18 09:01AM	BrainStorm Cell Therapeutics to Participate in Movement Disorder Panel at the Neurotech Investing and Partnering Conference PR Newswire
Apr-11-18 01:00AM	BrainStorm Cell Therapeutics to Present at ARM's 6th Annual Cell & Gene Therapy Investor Day, April 17 in New York PR Newswire
Mar-28-18 05:54AM	BrainStorm Cell Therapeutics' Phase 3 Trial of NurOwn® in ALS Now Open to Canadian Patients PR Newswire
Mar-21-18 08:00AM	BrainStorm Appoints Two Leading Thought Leaders in the Fields of Neuroscience and Regenerative Medicine to its Scientific Advisory Board PR Newswire
Mar-15-18 12:27PM	BrainStorm Cell Therapeutics to Present at the BIO Asia International Conference and the Wall Street Investor Forum PR Newswire
Mar-13-18 12:00PM	BCLI: Phase 3 Trial in ALS Enrolling Patients Zacks Small Cap Research
07:32AM	Innovate Biopharmaceuticals appoints June Almenoff, M.D., Ph.D. as Chief Operating Officer and Chief Medical Officer GlobeNewswire
Mar-12-18 01:00AM	BrainStorm Announces Formation of Scientific Advisory Board and Appoints Neuroscientist Jerold Chun, M.D., Ph.D., to Chair PR Newswire
Mar-08-18 06:45AM	Brainstorm Cell Therapeutics Inc. to Host Earnings Call ACCESSWIRE
06:30AM	BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017 PR Newswire
Mar-06-18 08:34AM	ALS patient group unhappy with how $115 million raised by the Ice Bucket Challenge is being spent MarketWatch
Mar-05-18 08:10AM	BrainStorm to Host an Annual Financial Results Call and Provide a Corporate Update on Thursday, March 8 PR Newswire
Feb-07-18 06:12AM	BrainStorm's NurOwn® Phase 2 ALS Clinical Trial and Biomarker Abstracts Accepted for Platform Presentations at the 70th Annual American Academy of Neurology Meeting in Los Angeles, California PR Newswire
Feb-06-18 05:35AM	BrainStorm Cell Therapeutics to Present at the BIO CEO & Investor Conference PR Newswire
Feb-05-18 06:01AM	BrainStorm Cell Therapeutics Appoints Senior Kite Executive, Anthony Polverino, Ph.D., to Board of Directors PR Newswire -5.12%
Jan-16-18 06:00AM	BrainStorm to Present at Precision Medicine World Conference 2018 Silicon Valley on January 22 PR Newswire
Jan-04-18 11:00AM	BCLI: Receives GMP Certification for NurOwn® Manufacturing Facility; Ready to Seek Approval Under Hospital Exemption in Israel Zacks Small Cap Research -5.04%
Jan-03-18 07:42AM	BrainStorm Granted GMP Certification for a Marketing-Level Manufacturing of NurOwn® PR Newswire
Dec-29-17 03:54AM	Brainstorm Issues 2017 Letter to Shareholders PR Newswire +29.37%
Dec-20-17 05:16AM	BrainStorm Cell Therapeutics to Present at the 10th Annual Biotech Showcase PR Newswire
Nov-29-17 06:29AM	BrainStorm's Abstracts on Phase 2 NurOwn® Biomarkers Accepted for Presentation at the International Symposium on ALS/MND in Boston PR Newswire
Nov-09-17 07:30AM	New Peer Reviewed Publication Shows That BrainStorm's NurOwn® Has a Unique miRNA Signature PR Newswire
Nov-02-17 09:03AM	BrainStorm Strengthens Executive Team: Appoints Eyal Rubin as Chief Financial Officer PR Newswire
Oct-23-17 09:29AM	BrainStorm Expands Its Patent Portfolio to Include a New US Patent For Its NurOwn® Technology for Parkinson's Disease And ALS PR Newswire
Oct-20-17 07:20AM	Corporate News Blog - Novan Acquires Intellectual Property Rights for Treating Viral Malignancies with Nitric Oxide ACCESSWIRE
Oct-19-17 07:10AM	Featured Company News - Syndax Pharma Signs Worldwide License Agreement for Allergan's Portfolio of Menin-MLL Inhibitors ACCESSWIRE
Oct-17-17 03:30PM	BCLI: Initiates Phase 3 Clinical Trial of NurOwn® in ALS Zacks Small Cap Research
07:00AM	BrainStorm Announces Third Quarter 2017 Financial Results PR Newswire
06:30AM	Investor Network: Brainstorm Cell Therapeutics Inc. to Host Earnings Call ACCESSWIRE
Oct-16-17 12:40AM	BrainStorm Enrolls First Patients in Phase 3 Trial of NurOwn® in ALS PR Newswire
12:05AM	BrainStorm enrolls first patients in advanced ALS stem cell trial Reuters
Oct-03-17 04:10PM	Brainstorm to Announce Third Quarter Financial Results And Provide Corporate Updates on Tuesday, October 17 PR Newswire
Sep-27-17 03:34AM	BrainStorm Cell Therapeutics to Present at the 2017 Disruptive Growth Company Showcase NYC Presented by SeeThruEquity and RHK Capital PR Newswire
Aug-23-17 01:00PM	BCLI: Phase 3 Trial of NurOwn® to Initiate Soon Zacks Small Cap Research

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in preclinical trial for the treatment of multiple sclerosis, Parkinson's disease, Huntington's disease, and autism spectrum disorder. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Almenoff June Sherie	Director	Jan 04	Buy	3.39	1,475	5,000	7,175	Jan 08 09:00 AM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience